Efficacy of Cognitive-Behavioral Therapy, in addition to standard systemic methotrexate therapy, in comparison with standard systemic methotrexate alone, in psoriasis
Not Applicable
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2019/08/020823
- Lead Sponsor
- Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with chronic plaque psoriasis with PASI score more than or equal to 10
Exclusion Criteria
Patients with psoriasis with contraindications to methotrexate therapy.
Patients with previous history of psychosis.
Patients with cognitive impairment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in disease severity (PASI) scoreTimepoint: Change in disease severity (PASI) scores will be assessed at each monthly visit for 3 months (0,1,2 and 3 months)
- Secondary Outcome Measures
Name Time Method Change in quality of life (DLQI) score and stress (PSLE and DHUS) scores, Change in biochemical markers of stress (CRH, ACTH,cortisol,DHEAS,Prolactin, DHEAS/Cortisol ratio,IL-17,SP, CGRP,Neuropeptide Y)Timepoint: Change in quality of life (DLQI) score and Stress (PSLE and DHUS) scores will be assessed at each monthly visit for 3 months (baseline,1,2 and 3 months). Biochemical markers of stress (CRH, ACTH, cortisol,DHEAS,Prolactin, <br/ ><br>DHEAS/Cortisol ratio,IL-17,SP, CGRP,Neuropeptide Y) will be assayed at baseline and at 3 months.